Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PR Newswire)
UF startup Dialectic Therapeutics has begun patient dosing in a clinical trial of its novel therapy for platinum-resistant ovarian cancer, marking a key milestone in its progress toward new treatment options.